$BLFS
BIOLIFE SOLUTIONS INC Stock $blfs

$blfs Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000114420417026646 Filed on May 12, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$2.366M	$1.852M
YoY Change	27.76%	23.41%
Cost Of Revenue	$928.4K	$771.0K
YoY Change	20.41%	24.74%
Gross Profit	$1.438M	$1.081M
YoY Change	33.0%	22.48%
Gross Profit Margin	60.76%	58.37%
Selling, General & Admin	$1.615M	$2.069M
YoY Change	-21.95%	20.24%
% of Gross Profit	112.33%	191.41%
Research & Development	$286.8K	$504.2K
YoY Change	-43.13%	56.52%
% of Gross Profit	19.94%	46.65%
Depreciation & Amortization	$89.55K	$91.79K
YoY Change	-2.44%	9.74%
% of Gross Profit	6.23%	8.49%
Operating Expenses	$1.902M	$2.573M
YoY Change	-26.1%	25.96%
Operating Profit	-$464.0K	-$1.492M
YoY Change	-68.91%	28.6%
Interest Expense	$83.33K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$406.3K	$1.919K
YoY Change	-21269.93%
Pretax Income	-$870.0K	-$1.490M
YoY Change	-41.61%	29.57%
Income Tax
% Of Pretax Income
Net Earnings	-$870.3K	-$1.227M
YoY Change	-29.06%	18.94%
Net Earnings / Revenue	-36.78%	-66.24%
Basic Earnings Per Share
Diluted Earnings Per Share	-$67.13K	-$98.72K
COMMON SHARES
Basic Shares Outstanding	13.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.300M	$1.700M
YoY Change	35.29%	-80.23%
Cash & Equivalents	$2.290M	$1.662M
Short-Term Investments		$0.00
Other Short-Term Assets	$400.0K	$400.0K
YoY Change	0.0%	33.33%
Inventory	$1.812M	$2.018M
Prepaid Expenses
Receivables	$1.061M	$1.190M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$5.582M	$5.307M
YoY Change	5.19%	-51.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.135M	$1.382M
YoY Change	-17.85%	-13.65%
Goodwill
YoY Change
Intangibles		$2.215M
YoY Change
Long-Term Investments	$1.800M
YoY Change
Other Assets	$0.00	$0.00
YoY Change
Total Long-Term Assets	$3.017M	$5.469M
YoY Change	-44.84%	30.22%
TOTAL ASSETS
Total Short-Term Assets	$5.582M	$5.307M
Total Long-Term Assets	$3.017M	$5.469M
Total Assets	$8.599M	$10.78M
YoY Change	-20.2%	-29.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$638.0K	$772.9K
YoY Change	-17.45%	-14.13%
Accrued Expenses	$69.33K	$113.3K
YoY Change	-38.83%	-71.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.086M	$1.480M
YoY Change	-26.65%	-1.33%
LONG-TERM LIABILITIES
Long-Term Debt	$3.900M	$0.00
YoY Change
Other Long-Term Liabilities	$800.0K	$800.0K
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$4.700M	$800.0K
YoY Change	487.5%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.086M	$1.480M
Total Long-Term Liabilities	$4.700M	$800.0K
Total Liabilities	$5.795M	$2.246M
YoY Change	158.01%	-47.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$72.10M	-$65.55M
YoY Change	9.99%
Common Stock	$74.90M	$73.00M
YoY Change	2.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.800M	$7.443M
YoY Change
Total Liabilities & Shareholders Equity	$8.599M	$10.78M
YoY Change	-20.2%	-29.11%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$870.3K	-$1.227M
YoY Change	-29.06%	18.94%
Depreciation, Depletion And Amortization	$89.55K	$91.79K
YoY Change	-2.44%	9.74%
Cash From Operating Activities	-$169.3K	-$1.590M
YoY Change	-89.35%	21.37%
INVESTING ACTIVITIES
Capital Expenditures	$37.15K	$26.94K
YoY Change	37.93%	-34.51%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$1.650M
YoY Change	-100.0%	-6.25%
Cash From Investing Activities	-$37.15K	$1.070M
YoY Change	-103.47%	-37.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.091M	10.00K
YoY Change	10806.0%	-50.0%
NET CHANGE
Cash From Operating Activities	-169.3K	-1.590M
Cash From Investing Activities	-37.15K	1.070M
Cash From Financing Activities	1.091M	10.00K
Net Change In Cash	884.1K	-510.0K
YoY Change	-273.35%	-218.6%
FREE CASH FLOW
Cash From Operating Activities	-$169.3K	-$1.590M
Capital Expenditures	$37.15K	$26.94K
Free Cash Flow	-$206.5K	-$1.617M
YoY Change	-87.23%	19.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	419124	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	1812172	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	270814	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	1757784	USD
CY2017Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1284491	USD
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1284491	USD
CY2017Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	667213	USD
CY2016Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	650912	USD
CY2017Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	943071	USD
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	922220	USD
CY2017Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2894775	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2857623	USD
CY2017Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1759794	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1670245	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1134981	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1187378	USD
CY2017Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	36166	USD
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	36166	USD
CY2017Q1	us-gaap	Assets Assets	8598774	USD
CY2016Q4	us-gaap	Assets Assets	7926614	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	638014	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	710719	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	69327	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	116399	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	248023	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	175829	USD
CY2017Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	130216	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	130216	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1085580	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1133163	USD
CY2017Q1	blfs	Deferred Rent Long Term DeferredRentLongTerm	590716	USD
CY2016Q4	blfs	Deferred Rent Long Term DeferredRentLongTerm	685450	USD
CY2017Q1	us-gaap	Liabilities Liabilities	5795088	USD
CY2016Q4	us-gaap	Liabilities Liabilities	4760474	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	13017	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	12864	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	74891236	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	74355645	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71202369	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8598774	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7926614	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2803686	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3166140	USD
CY2017Q1	blfs	Investment In Biologistex InvestmentInBiologistex	1845632	USD
CY2016Q4	blfs	Investment In Biologistex InvestmentInBiologistex	2075000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	5581995	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	4628070	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72100567	USD
CY2017Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	928402	USD
CY2016Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	771005	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	1437799	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	1081012	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286751	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	504239	USD
CY2017Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	511944	USD
CY2016Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	733913	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1103143	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1335292	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	1901838	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	2573444	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-464039	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1492432	USD
CY2017Q1	us-gaap	Other Income OtherIncome	48	USD
CY2016Q1	us-gaap	Other Income OtherIncome	1919	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	-870290	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	-1490513	USD
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-263685	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-870290	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-1226828	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12964639	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12457858	shares
CY2017Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	83333	USD
CY2016Q1	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	93598	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-406251	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1919	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1852017	USD
CY2017Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2016Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	451	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	0	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-451	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-263685	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-870290	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1490062	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-870290	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1226377	USD
CY2017Q1	us-gaap	Depreciation Depreciation	89549	USD
CY2016Q1	us-gaap	Depreciation Depreciation	91791	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	329895	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	146527	USD
CY2017Q1	blfs	Deferred Rent Amortization DeferredRentAmortization	-31750	USD
CY2016Q1	blfs	Deferred Rent Amortization DeferredRentAmortization	-31749	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-510827	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1662431	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1070529	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1090600	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12127	USD
CY2016Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1792	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-132873	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	260971	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	54388	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	183620	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	138029	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-17324	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11970	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	91907	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	41447	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	10694	USD
CY2017Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	83333	USD
CY2016Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2017Q1	blfs	Deferred Rent DeferredRent	-62984	USD
CY2016Q1	blfs	Deferred Rent DeferredRent	13335	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-169348	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1593483	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Trading Securities Heldforinvestment ProceedsFromSaleAndMaturityOfTradingSecuritiesHeldforinvestment	0	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Trading Securities Heldforinvestment ProceedsFromSaleAndMaturityOfTradingSecuritiesHeldforinvestment	1650000	USD
CY2017Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	0	USD
CY2016Q1	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	552535	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37152	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26936	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-37152	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	884100	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2173258	USD
CY2017Q1	us-gaap	Deposits Fair Value Disclosure DepositsFairValueDisclosure	2236718	USD
CY2017Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	53208	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2289926	USD
CY2017Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	2289926	USD
CY2016Q4	us-gaap	Deposits Fair Value Disclosure DepositsFairValueDisclosure	1352541	USD
CY2016Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	53285	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1405826	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	1405826	USD
CY2017Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	437892	USD
CY2016Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	531053	USD
CY2017Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	241057	USD
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	370740	USD
CY2017Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1133223	USD
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	855991	USD
CY2017Q1	blfs	Leasehold Improvements Gross1 LeaseholdImprovementsGross1	1124790	USD
CY2016Q4	blfs	Leasehold Improvements Gross1 LeaseholdImprovementsGross1	1124790	USD
CY2017Q1	blfs	Leasehold Improvements LeaseholdImprovements	590513	USD
CY2016Q4	blfs	Leasehold Improvements LeaseholdImprovements	622263	USD
CY2017Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	720932	USD
CY2016Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	815666	USD
CY2017Q1	blfs	Less Accumulated Amortization LessAccumulatedAmortization	534277	USD
CY2016Q4	blfs	Less Accumulated Amortization LessAccumulatedAmortization	502527	USD
CY2017Q1	blfs	Straight Line Rent Adjustment StraightLineRentAdjustment	130419	USD
CY2016Q4	blfs	Straight Line Rent Adjustment StraightLineRentAdjustment	193403	USD
CY2017Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	34064	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	329895	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	146527	USD
CY2017Q1	us-gaap	Area Of Land AreaOfLand	30000	sqft
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	BIOLIFE SOLUTIONS INC
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000834365
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q1	dei	Trading Symbol TradingSymbol	BLFS
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13036621	shares
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	15798	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13016533	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13016533	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12863824	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12863824	shares
CY2017Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-229368	USD
CY2016Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2017Q1	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	3937602	USD
CY2016Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	2844004	USD
CY2017Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	181190	USD
CY2016Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	97857	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	62398	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	155996	USD
CY2017Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	USD
CY2016Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	120000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	32223	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	29400	USD
CY2016Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	20096	USD
CY2017Q1	blfs	Option Exercises For Which Cash Not Yet Received OptionExercisesForWhichCashNotYetReceived	0	USD
CY2016Q1	blfs	Option Exercises For Which Cash Not Yet Received OptionExercisesForWhichCashNotYetReceived	13989	USD
CY2017Q1	blfs	Deferred Costs Related To Security Issuance Not Yet Paid DeferredCostsRelatedToSecurityIssuanceNotYetPaid	7856	USD
CY2016Q1	blfs	Deferred Costs Related To Security Issuance Not Yet Paid DeferredCostsRelatedToSecurityIssuanceNotYetPaid	66640	USD
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"> Concentrations of credit risk and business risk</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">In the three months ended March 31, 2017, we derived approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21</font>% of our product revenue from two customers. In the three months ended March 31, 2016, we derived approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% of our product revenue from one customer. No other customer accounted for more than 10% of revenue in the three months ended March 31, 2017 or 2016. At March 31, 2017, one customer accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 22</font>% of total gross accounts receivable. At December 31, 2016, three customers accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 45</font>% of total gross accounts receivable. </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Revenue from customers located in foreign countries represented <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 22</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21</font>% of total revenue during the three months ended March 31, 2017 and 2016, respectively. All revenue from foreign customers are denominated in United States dollars. </font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0207	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0165	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.75	pure
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.75	pure
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y2M5D
CY2017Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	7603141	USD
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	7603141	USD
CY2017Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.46
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.46
CY2017Q1	blfs	Outstanding Warrants Expiration Dates OutstandingWarrantsExpirationDates	The outstanding warrants have expiration dates between May 2017 and May 2021.
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	531250	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1062500	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1062500	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	1062500	USD
CY2017Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	531250	USD
CY2017Q1	us-gaap	Long Term Debt LongTermDebt	4250000	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3000000	USD
CY2016Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	3000000	USD
CY2017Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4000000	USD
CY2017Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	4000000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.13
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.29
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	70714	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4253	USD
CY2017Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	295831	USD
CY2016Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	47809	USD
CY2016Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	98718	USD
CY2017Q1	us-gaap	Cumulative Effect On Retained Earnings Net Of Tax1 CumulativeEffectOnRetainedEarningsNetOfTax1	27908	USD
CY2017Q1	us-gaap	Cumulative Effect On Retained Earnings Net Of Tax1 CumulativeEffectOnRetainedEarningsNetOfTax1	-27908	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1060773	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1193646	USD
CY2017Q1	us-gaap	Stock Issued1 StockIssued1	35624	USD
CY2016Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2343697	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
CY2016Q1	blfs	Estimated Forfeiture Rate EstimatedForfeitureRate	0.081	pure
CY2017Q1	blfs	Monthly Base Rent Expense MonthlyBaseRentExpense	57000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	100000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options have an exercise price of $1.64, and if revenue levels are met, vest 50% on the release of the Company’s audited financial statements for 2017, and 50% one year thereafter. If the minimum performance targets are not achieved, no options will vest.

Files In Submission

Name	View Source	Status
0001144204-17-026646-index-headers.html	Edgar Link	pending
0001144204-17-026646-index.html	Edgar Link	pending
0001144204-17-026646.txt	Edgar Link	pending
0001144204-17-026646-xbrl.zip	Edgar Link	pending
blfs-20170331.xml	Edgar Link	completed
blfs-20170331.xsd	Edgar Link	pending
blfs-20170331_cal.xml	Edgar Link	unprocessable
blfs-20170331_def.xml	Edgar Link	unprocessable
blfs-20170331_lab.xml	Edgar Link	unprocessable
blfs-20170331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
logo_10q.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v466194_10q.htm	Edgar Link	pending
v466194_ex31-1.htm	Edgar Link	pending
v466194_ex31-2.htm	Edgar Link	pending
v466194_ex32-1.htm	Edgar Link	pending
v466194_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BLFS
BIOLIFE SOLUTIONS INC Stock $blfs

2017 Q1 Form 10-Q Financial Statement

#000114420417026646 Filed on May 12, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLFS BIOLIFE SOLUTIONS INC Stock $blfs

2017 Q1 Form 10-Q Financial Statement

#000114420417026646 Filed on May 12, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLFS
BIOLIFE SOLUTIONS INC Stock $blfs